Avalyn Pharmaceuticals

Executive Summary

Avalyn Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted inhaled therapies for rare respiratory diseases, primarily pulmonary fibrosis and interstitial lung diseases (ILDs). Its lead product candidates, AP01 for progressive pulmonary fibrosis and AP02 for idiopathic pulmonary fibrosis (IPF), are both in Phase 2 clinical trials. The inhaled delivery approach aims to enhance drug efficacy in lung tissue while minimizing systemic side effects, addressing a significant unmet need in fibrotic lung diseases. Avalyn was founded in 2019 and is based in Seattle, Washington. With both programs advancing in the clinic, the company represents a focused player in the respiratory orphan drug space.

Upcoming Catalysts (preview)

• Q4 2026AP01 Phase 2 interim data readout in progressive pulmonary fibrosis60% success
• Q3 2026AP02 Phase 2 initiation and early efficacy signals in IPF55% success